We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+8.62%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.71B
AUM Growth
+$201M
Cap. Flow
+$66M
Cap. Flow %
1.4%
Top 10 Hldgs %
37.6%
Holding
120
New
15
Increased
43
Reduced
17
Closed
23

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$135M
2
AZN icon
AstraZeneca
AZN
+$85.6M
3
BAX icon
Baxter International
BAX
+$72.7M
4
AVTR icon
Avantor
AVTR
+$60.9M
5
UNH icon
UnitedHealth
UNH
+$55.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$126M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$92.2M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$39.7M
4
EXAS
Exact Sciences
EXAS
+$35.2M
5
CMPS
Compass Pathways
CMPS
+$34.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 0.5%
3 Technology 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
101
DELISTED
Exact Sciences
EXAS
– –
-369,000
Closed -$35.2M
GHRS icon
102
GH Research
GHRS
$1.94B
– –
-560,000
Closed -$12.4M
NBP
103
NovaBridge Biosciences American Depositary Shares
NBP
$192M
– –
-454,000
Closed -$32.9M
KROS icon
104
Keros Therapeutics
KROS
$199M
– –
-145,100
Closed -$5.74M
LFST icon
105
Lifestance Health
LFST
$4.21B
– –
-1,000,000
Closed -$14.5M
NAUT icon
106
Nautilus Biotechnolgy
NAUT
$144M
– –
-600,000
Closed -$3.68M
NTLA icon
107
Intellia Therapeutics
NTLA
$1.53B
– –
-251,000
Closed -$33.7M
PATH icon
108
UiPath
PATH
$6.58B
– –
-319,000
Closed -$16.8M
REGN icon
109
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-152,300
Closed -$92.2M
SANA icon
110
Sana Biotechnology
SANA
$888M
– –
-774,644
Closed -$17.4M
SGHT icon
111
Sight Sciences
SGHT
$292M
– –
-145,189
Closed -$3.3M
XBI icon
112
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-3,021,000
Closed -$380M
ZETA icon
113
Zeta Global
ZETA
$5.63B
– –
-1,300,000
Closed -$7.62M
ZLAB icon
114
Zai Lab
ZLAB
$2.07B
– –
-35,600
Closed -$3.75M
ESMT
115
DELISTED
EngageSmart, Inc.
ESMT
– –
-275,000
Closed -$9.37M
ORTX
116
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-383,680
Closed -$8.82M
HARP
117
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-119,060
Closed -$9.41M
HCAQ
118
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
– –
-500,000
Closed -$4.95M
XLRN
119
CALL
DELISTED
Acceleron Pharma
XLRN
– –
-1,228,100
Closed -$211M
XLRN
120
DELISTED
Acceleron Pharma
XLRN
– –
-35,000
Closed -$6.02M
1 2 3 4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2021 Portfolio in Review

As of Q4 2021, Avidity Partners Management held 120 positions worth $4.71B, up 4.5% from $4.51B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Avidity Partners Management's Q4 2021 filing shows 15 new, 43 increased, 17 reduced and 23 closed positions. Its largest new stake was Elevance Health: 321,000 shares worth $149M. The largest sale was Vertex Pharmaceuticals, an estimated $126M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 85% a quarter earlier, followed by Financials and Technology.

  • Avidity Partners Management's largest Q4 2021 buy was Elevance Health: 321,000 shares worth $149M.
  • Avidity Partners Management added most to AstraZeneca in Q4 2021, an estimated $85.6M increase.
  • Avidity Partners Management's biggest Q4 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $126M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q4 2021, selling an estimated $92.2M.
  • Avidity Partners Management's ten largest holdings make up 38% of its $4.71B portfolio in Q4 2021.
  • Avidity Partners Management opened 15 new positions and closed 23 in Q4 2021.
  • Avidity Partners Management's portfolio value rose 4.5% quarter-over-quarter to $4.71B.

Based on Avidity Partners Management's 13F filing for Q4 2021, filed 14 Feb 2022.